Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia

详细信息    查看全文

• 作者：Neethu N. Menon ; Lydia M. Jenkins ; Haiyan Cui ; Craig Jenkins…
• 关键词：Second allogeneic hematopoietic cell transplant ; Leukemia ; Relapse
• 刊名：Annals of Hematology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：95
• 期：4
• 页码：637-644
• 全文大小：419 KB
• 参考文献：1.Barrett AJ, Battiwalla M (2010) Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 3(4):429–441CrossRef PubMed PubMedCentral
  2.Shaw BE, Russell NH (2008) Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplantation 41(5):495–503CrossRef PubMed
  3.Frassoni F, Barrett AJ, Granena A, Ernst P, Garthon G, Kolb HJ, Prentice HG, Vernant JP, Zwaan FE, Gratwohl A (1988) Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. British Journal of Haematology 70(3):317–320CrossRef PubMed
  4.Kobayashi K, Kami M, Murashige N, Kusumi E, Kishi Y, Hamaki T, Hori A, Matsumura T, Yuji K, Masuo S, Mori S, Miyakoshi S, Tanosaki R, Mitamura T, Takaue Y, Taniguchi S, Tokyo SCTCI (2005) Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. British Journal of Haematology 129(6):795–802CrossRef PubMed
  5.Chueh HW, Lee SH, Sung KW, Yoo KH, Koo HH (2013) Second allogeneic stem cell transplantation in hematologic malignancies: a single-center experience. Journal of Pediatric Hematology/Oncology 35(6):424–429CrossRef PubMed
  6.Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, Gottschalk S, Brenner M, Heslop H, Krance R (2015) Outcomes after second hematopoietic stem cell transplantations in pediatric patients with relapsed hematological malignancies. Biology of Blood and Marrow Transplantation 21(7):1266–1272CrossRef PubMed
  7.Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W, McDonald GB, Mori M, Schoch G, Hansen JA (1993) Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. Journal of Clinical Oncology 11(2):304–313PubMed
  8.Bajwa R, Schechter T, Soni S, Gassas A, Doyle J, Sisler I, Godder K, Tatman D, Rumelhart S, Domm J, Miao Y, Frangoul H (2013) Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplantation 48(5):661–665CrossRef PubMed
  9.Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, Sanders JE (2003) Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biology of Blood and Marrow Transplantation 9(11):706–713CrossRef PubMed
  10.Kato M, Horikoshi Y, Okamoto Y, Takahashi Y, Hasegawa D, Koh K, Takita J, Inoue M, Kigasawa H, Ogawa A, Sasahara Y, Kawa K, Yabe H, Sakamaki H, Suzuki R, Kato K (2012) Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplantation 47(10):1307–1311CrossRef PubMed
  11.Munoz A, Badell I, Olive T, Verdeguer A, Gomez P, Bureo E (2002) Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON). Haematologica 87(3):331–332PubMed
  12.Kedmi M, Resnick IB, Dray L, Aker M, Samuel S, Gesundheit B, Slavin S, Or R, Shapira MY (2009) A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biology of Blood and Marrow Transplantation 15(4):483–489CrossRef PubMed
  13.Oda M, Isoyama K, Ito E, Inoue M, Tsuchida M, Kigasawa H, Kato K, Kato S (2009) Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. International Journal of Hematology 89(3):374–382CrossRef PubMed
  14.Hanajiri R, Ohashi K, Hirashima Y, Kakihana K, Kobayashi T, Yamashita T, Sakamaki H, Akiyama H (2012) Second allogeneic transplantation for relapsed acute leukemia after initial allogeneic hematopoietic stem cell transplantation. Pathology Oncology Research 18(4):1003–1008CrossRef PubMed
  15.Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE (1991) Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. British Journal of Haematology 79(4):567–574CrossRef PubMed
  16.Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S (1997) Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplantation 20(2):129–135CrossRef PubMed
  17.Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, Gajewski JL, Gale RP, Herzig RH, Prentice HG et al (1992) Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplantation 9(4):269–275PubMed
  18.Al-Qurashi F, Ayas M, Al Sharif F, Ibrahim E, Sahovic E, Al Mahr M, Chaudhri N, Al Mohareb F, Al Zahrani H, Al Jefri A, Al Omar H, Al Shanqeeti A, Seth P, Aslam M, El Solh H, Aljurf M (2004) Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution. Hematology 9(2):123–129CrossRef PubMed
  19.Isoyama K, Ohnuma K, Ikuta K, Toyoda Y, Nakajima F, Yamada K, Nishihira H, Kanagawa Cord Blood B (2003) Unrelated cord blood transplantation for second hemopoietic stem cell transplantation. Pediatr Int 45(3):268–274CrossRef PubMed
  
• 作者单位：Neethu N. Menon (1)
  Lydia M. Jenkins (1)
  Haiyan Cui (5)
  Craig Jenkins (3)
  Faiz Anwer (3) (5)
  Andrew M. Yeager (1) (3) (5)
  Emmanuel Katsanis (1) (2) (3) (4) (5)
  
  1. Department of Pediatrics, University of Arizona, PO Box 245073, 1501 N. Campbell Ave., Tucson, AZ, 85724-5073, USA
  5. University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
  3. Department of Medicine, University of Arizona, Tucson, AZ, USA
  2. Department of Immunobiology, University of Arizona, Tucson, AZ, USA
  4. Department of Pathology, University of Arizona, Tucson, AZ, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

A second allogeneic (allo) hematopoietic cell transplant (HCT) is an important therapeutic consideration for patients relapsing after their first. We conducted a retrospective review of 41 pediatric patients with leukemia that underwent a second allo-HCT at our institution. Overall, 53.7 and 43.9 % of patients were alive and disease-free at 1 and 5 years, respectively, after the second allo-HCT. The factors affecting outcome by both univariate and multivariate analysis were interval between transplants and the use of a myeloablative conditioning (MAC) regimen prior to second transplant. Outcomes were inferior in patients who received their second transplant <6 months from their first HCT when compared to patients in whom the interval between HCTs was 6–12 or more than 12 months. Interval between HCTs was also significant when each type of leukemia (acute lymphoblastic leukemia (ALL) n = 21, acute myelogenous leukemia (AML) n = 11, and chronic myelogenous leukemia (CML) n = 7) was analyzed separately. In univariate analysis, use of the same donor and use of a matched sibling donor resulted in significant improved outcome. There was not a significant association between disease-free survival (DFS) and age, remission status, use of total body irradiation (TBI) before second HCT, or type of leukemia. Second allogeneic HCT can be a curative therapeutic option for leukemia patients relapsing after their first transplant. As more targeted therapies have become available, patients that relapse after first HCT are more likely to achieve remission. Therefore, it is anticipated that there will be more candidates for second HCT with improved performance and remission status, ultimately leading to a better outcome with the second HCT.